Arcturus Therapeutics (ARCT)
US Market

Arcturus Therapeutics Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

3 Buy
3 Hold
2 Sell
Based on 8 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARCT Stock Price Prediction

Average Price Target

▲(154.58% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $40.86 with a high forecast of $98.00 and a low forecast of $16.00. The average price target represents a 154.58% change from the last price of $16.05.
Highest Price Target$98.00Average Price Target$40.86Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
Arcturus Therapeutics (ARCT) Announces Positive PhI/II Data - LaidlawThe analyst stated "We view todays news encouraging as ARCT-154 has clinically demonstrated its potential as a promising booster vaccine prospect against Covid. Since the initial vaccinations against Covid have been done in most countries, booster vaccines are likely to be one of the near-term commercial opportunities going forward. We anticipate outcomes from a longer follow-up beyond three months could be valuable to assess the durability of ARCT-154 boost effect."
Piper Sandler
Piper says do not be fooled, Arcturus Phase 3 shows strong vaccine efficacy 08:3004/20/2204/2008:3004/20/2208:30Piper says do not be fooled, Arcturus Phase 3 shows strong vaccine efficacy
J.P. Morgan
Arcturus Therapeutics price target lowered to $86 from $93 at Cantor FitzgeraldArcturus Therapeutics price target lowered to $86 from $93 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is $40.86.
    What is ARCT’s upside potential, based on the analysts’ average price target?
    Arcturus Therapeutics has 154.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARCT a Buy, Sell or Hold?
          Arcturus Therapeutics has a conensus rating of Hold which is based on 3 buy ratings, 3 hold ratings and 2 sell ratings.
            What is Arcturus Therapeutics’s price target?
            The average price target for Arcturus Therapeutics is $40.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $98.00 ,the lowest forecast is $16.00. The average price target represents 154.58% Increase from the current price of $16.05.
              What do analysts say about Arcturus Therapeutics?
              Arcturus Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 8 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis